Researchers at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla have found evidence to explain the varying responses of cancer patients to cisplatin, a common chemotherapy drug that is the first-line therapy for testicular and ovarian cancers. Findings published online on September 3 in the Proceedings of the National Academy of Sciences demonstrated that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

October 2008 - Table of Contents

DTTR October 2008 (full PDF issue)

Myriad Genetics May Spin Off Pharma Business

FDA Clears Third IVDMIA: XDx’s AlloMap

Nanogen to Merge With French Diagnostics Company

Meridian Bioscience Inks Canadian Distribution Deal

Inside the Diagnostics Industry: Nanogen’s David Ludvigson on Mergers, Markets, and Microarrays

New Gene Variant Linked to Prostate Cancer Risk

Protein Variant Predicts Chemotherapy Response

Pathwork Diagnostics Raises $20 Million

Pall Corporation Acquires GeneSystems

Physicians Frustrated by CMS’s Quality Reporting Initiative Feedback

IVD Stocks Down 6%; OraSure, Luminex Only Gainers

Biomarker for Soft Tissue Sarcoma